About
EyeControl is a medical technology company revolutionizing ICU care with its AI-powered eye-tracking platform. Designed to empower mechanically ventilated patients, it enables effective communication, connects families and caregivers, and provides healthcare teams with actionable insights. By supporting implementation of evidence-based practices for optimizing critical care, EyeControl enhances patient safety, improves cognitive and mental health outcomes, and fosters meaningful connections.
The EyeControl device is FDA-listed, CE-marked, ISO-certified, and AMAR and MAKAT registered as a communication solution. It is federally reimbursed in Israel for inpatient settings and homecare.
Funding history · 5 rounds · $15.2M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is EyeControl's primary focus in medical technology?
- EyeControl is a medical technology company that develops an AI-powered eye-tracking platform to facilitate communication for mechanically ventilated patients in ICU care.
- When was EyeControl founded and where is its headquarters located?
- EyeControl was founded in January 2016 and is headquartered in Bnei Brak, Israel.
- What was EyeControl's initial funding round?
- EyeControl secured its first funding, a Crowdfunding round of $50,000, in August 2015 from Indiegogo.
- Which investor led EyeControl's Series A funding round?
- In August 2020, EyeControl raised $7,500,000 in a Series A round, led by Connecticut Innovations.
- What is the total amount of funding EyeControl has raised to date?
- EyeControl has raised a total of $15,213,000 across its funding rounds. For a full financing history, please refer to startupim.
- What is the current employee count for EyeControl?
- EyeControl currently has 22 employees.
- What certifications and registrations does the EyeControl device hold?
- The EyeControl device is FDA-listed, CE-marked, ISO-certified, and AMAR and MAKAT registered as a communication solution. It is also federally reimbursed in Israel for inpatient settings and homecare.
- What was a significant development in EyeControl's R&D program in June 2022?
- In June 2022, EyeControl expanded its R&D program with EyeControl-Pro, focusing on delirium.
- What was the most recent funding activity for EyeControl?
- EyeControl's most recent funding activity was an Equity crowdfunding round in April 2025, with ExitValley as an investor.